Teladoc (NYSE:TDOC) – Cantor Fitzgerald raised their FY2019 earnings per share (EPS) estimates for shares of Teladoc in a research note issued on Tuesday, May 22nd. Cantor Fitzgerald analyst S. Halper now anticipates that the health services provider will post earnings of ($0.40) per share for the year, up from their previous estimate of ($0.41). Cantor Fitzgerald has a “Hold” rating and a $35.00 price objective on the stock.
Several other equities analysts have also recently commented on the stock. SunTrust Banks raised their target price on shares of Teladoc to $48.00 and gave the company a “positive” rating in a research note on Wednesday, May 2nd. Craig Hallum set a $39.00 target price on shares of Teladoc and gave the company a “hold” rating in a research note on Wednesday, May 2nd. ValuEngine raised shares of Teladoc from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Canaccord Genuity reissued a “buy” rating and set a $45.00 target price on shares of Teladoc in a research note on Friday, April 13th. Finally, Wells Fargo & Co set a $46.00 target price on shares of Teladoc and gave the company a “buy” rating in a research note on Friday, April 6th. One research analyst has rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $42.67.
Teladoc (NYSE:TDOC) last released its earnings results on Tuesday, May 1st. The health services provider reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.04. The firm had revenue of $89.64 million for the quarter, compared to analysts’ expectations of $86.77 million. Teladoc had a negative net margin of 41.06% and a negative return on equity of 20.40%. Teladoc’s quarterly revenue was up 109.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.30) EPS.
In other news, insider Adam C. Vandervoort sold 47,123 shares of Teladoc stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $39.36, for a total value of $1,854,761.28. Following the transaction, the insider now directly owns 19,338 shares of the company’s stock, valued at $761,143.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jason N. Gorevic sold 40,000 shares of Teladoc stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $43.27, for a total transaction of $1,730,800.00. The disclosure for this sale can be found here. Insiders sold a total of 483,954 shares of company stock worth $19,960,682 in the last ninety days. Corporate insiders own 3.95% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in TDOC. Carillon Tower Advisers Inc. purchased a new position in shares of Teladoc in the fourth quarter worth approximately $57,973,000. Global Thematic Partners LLC purchased a new position in shares of Teladoc in the first quarter worth approximately $51,465,000. Champlain Investment Partners LLC purchased a new position in shares of Teladoc in the fourth quarter worth approximately $29,290,000. Alliancebernstein L.P. increased its position in shares of Teladoc by 15.7% in the fourth quarter. Alliancebernstein L.P. now owns 4,472,612 shares of the health services provider’s stock worth $155,871,000 after acquiring an additional 607,002 shares in the last quarter. Finally, Bamco Inc. NY increased its position in shares of Teladoc by 32.7% in the fourth quarter. Bamco Inc. NY now owns 1,931,500 shares of the health services provider’s stock worth $67,313,000 after acquiring an additional 475,600 shares in the last quarter.
Teladoc Company Profile
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.